Inovio Clinical Trials: Cancer

Inovio Pharmaceuticals or its partners/collaborators are conducting clinical trials for the treatment of several types of cancers. Patients are now being recruited for these trials. Please visit the links below for more information.

If you are interested in participating in a study, it is important that you discuss the study with your doctor.

Inovio is committed to the safety of patients who take part in our trials, and we uphold the highest ethical standards in all of our research initiatives.

Indications: Cervical dysplasia / cancer caused by human papillomavirus (HPV)

Treatment: VGX-3100

Study title: Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation with CELLECTRA®-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 with Documented HPV 16 or 18

Trial Stage: Phase II

Status: Enrolling.

Click this link for further information regarding this clinical study.

Indications: Acute and chronic myeloid leukemia (Partner/Sponsor: University of Southampton)

Treatment: DNA vaccine encoding for Wilms' tumor gene 1 (WT1)

Study title: WT1 Immunity via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (WIN)

Trial Stage: Phase II

Status: Enrolling

http://clinicaltrials.gov/ct2/show/NCT01334060?term=leukemia+southampton&rank=1

Indications: Breast, lung, prostate & other cancers

Treatment: V934/V935

Study title: A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors

Trial Stage: Phase I

Status: Enrollment has been completed.